This Solicitation opportunity from Agency For International Development was posted on February 8, 2021. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

BAA Addendum Microbicides R&D

Closed

GlobalHealthBAA-Microbicides-2021Federal

Submission Closed03/11/2021, 04:59:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714

New

Federal

Presolicitation Notice - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response

Solicitation # 75A50126R00001_RFP_PreSolNotice_NPIVS-2027

BARDA is seeking qualified contractors to support the ongoing Vaccine Medical Countermeasures for Pandemic Influenza Preparedness and Response Program, requiring the provision of vaccines, antigens, and adjuvants to ensure rapid readiness for pandemic influenza or other viruses with pandemic potential. Contractors must deliver comprehensive services including manufacturing, regulatory documentation, and manufacturing readiness support, with a preference for U.S. based facilities. This includes generating and submitting all necessary analytical, nonclinical, clinical, and CMC data to the FDA, even during interpandemic periods, to enable timely regulatory decisions and sustain production capability. The program emphasizes continuous improvement of influenza vaccines with demonstrated feasibility and full lifecycle support from development through commercial-scale manufacturing. To be eligible, offerors must have a proven track record in influenza vaccine manufacturing, either by holding an active U.S. influenza vaccine license or by having successfully submitted a Biologics License Application for a seasonal or pandemic influenza vaccine. The solicitation, issued under number 75A50126R00001_RFP_PreSolNotice_NPIVS-2027, is open with a response deadline of August 15, 2026, and is administered by the Department of Health and Human Services through BARDA. All proposals must meet strict qualification criteria and align with the program’s goals of ensuring national preparedness, rapid response capacity, and regulatory compliance. Primary point of contact for inquiries is Laura Saddison at HHS.

Barda - Aspr / Daappo / Barda Dcma

POSTED

DEADLINE

Convergence Special Notice

Solicitation # DARPA-SN-26-108

The Convergence program seeks to revolutionize environmental monitoring for defense operations by integrating synthetic biology and engineering to create advanced microbial biosensors capable of detecting chemical and pharmaceutical hazards in austere environments. Leveraging non-pathogenic microbial consortia built on well-characterized, safe host organisms like E. coli, the initiative focuses on developing modular biological systems that translate environmental inputs into standardized, detectable outputs. The program’s development follows a structured four-tiered approach, progressing from component-level design and integrated payload engineering to full system integration within a microbial chassis, ultimately aiming for a deployable platform ready for U.S. and international regulatory certification. This systematic progression ensures that each layer of functionality is rigorously validated before scaling to operational readiness. To enable safe, responsible, and globally viable deployment, the program includes a dedicated ecosystem of testing and collaboration. Performance and safety validation will first occur within the United States before exploring international adoption, with two specialized working groups guiding the process: one focused on navigating socio-political landscapes and local environmental regulations, and another managing cooperative use cases and deployment protocols with global allies. Administered by DARPA, the solicitation under number DARPA-SN-26-108 invites multidisciplinary teams in synthetic biology, environmental science, and engineering to contribute to this initiative, with responses due by August 6, 2026. The program is headquartered in Arlington, Virginia, and is led by Mark Salvador, with the goal of delivering a scalable, secure, and globally interoperable biosensor platform for the protection of military personnel.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

Multimodal Sensor Integration and Signal Fusion EngineeringThe contract seeks integration of multiple sensing modalities into a unified platform designed for real-time pharmaceutical inspection, emphasizing synchronized signal correlation and advanced noise reduction techniques. The project requires the engineering of a robust system capable of fusing data from diverse sensor types to enhance detection accuracy, reliability, and speed in identifying product defects or anomalies during manufacturing processes. Development must ensure temporal and spatial alignment of signals, adaptive filtering for environmental and operational interference, and seamless interoperability across hardware and software components to support continuous, high-fidelity monitoring. This subcontract, under NAICS code 541714 and sponsored by the Advanced Research Projects Agency for Health within the Department of Health and Human Services, targets innovation in sensor fusion technologies with a specific focus on quality assurance in pharmaceutical production. The place of performance is designated as Washington DC with a zip code of 20005, and proposals must be submitted by August 20, 2026. The initiative aims to advance detection capabilities beyond conventional single-sensor approaches, enabling next-generation inspection systems that meet stringent regulatory standards through data-driven, real-time analytics.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

Sources Sought – RRBS Sequencing Services

Solicitation # 36C241-26-AP-4037

The Department of Veterans Affairs is seeking qualified Service-Disabled Veteran-Owned Small Businesses and Veteran-Owned Small Businesses to provide Reduced Representation Bisulfite Sequencing services for a neurodegenerative disease research program involving approximately 269 de-identified human post-mortem choroid plexus tissue samples. The scope includes comprehensive sample handling and quality control, bisulfite conversion, library preparation, Illumina paired-end sequencing generating about 30 million read pairs per sample, and downstream bioinformatics analysis such as raw data alignment, methylation calling, and genome browser track generation, with an expected turnaround time of six to eight weeks. This notice is issued for market research purposes under the Veterans First Contracting Program and is intended to evaluate potential for a set-aside under the VA Rule of Two, ensuring opportunities for SDVOSBs and VOSBs. All interested parties must submit a capability statement detailing their technical expertise, business size and status as an SDVOSB or VOSB, and facility location by 11:00 AM EST on August 12, 2026, to Chelsea Cortright at Chelsea.Cortright@va.gov with the subject line referencing ID# 36C241-26-AP-4037. The opportunity is not a solicitation or request for proposals, and no contract will be awarded directly from this notice. The effort is managed by the 241-NETWORK Contract Office 01 based in Togus, Maine, with performance occurring in Bedford, Massachusetts, under NAICS code 541714 for analytical laboratory services. Additional inquiries can be directed to Jennifer Fiore, the secondary point of contact.

241-NETWORK Contract Office 01 (36C241)

POSTED

DEADLINE

Automated Anatomical Segmentation of Brain RegionsThe contract seeks to deliver an automated computational method for segmenting 3D brain images into more than 820 precisely defined anatomical regions, enabling high-resolution neural mapping. This work relies on artificial intelligence or atlas-based algorithms to accurately identify and delineate complex brain structures, supporting advanced neuroscientific research and clinical applications. The project demands robust, reproducible, and scalable software capable of processing diverse neuroimaging data while maintaining consistent precision across the full spectrum of targeted regions. Issued as a subcontract under the NAICS code 541714 by the National Institutes of Health through the Department of Health and Human Services, the effort is focused on performance in Bethesda, Maryland, with a response deadline of August 5, 2026. The solicitation was posted on July 27, 2026, and no specific set-aside status or point of contact details are provided. All proposals must demonstrate technical capability in AI-driven medical image analysis and the ability to meet the stringent requirements of anatomical segmentation at a scale and accuracy required for detailed brain mapping.

National Institutes Of Health Olao

POSTED

DEADLINE

Research service necessary to execute a NAMRU SOUTH Zika study in Panama.

Solicitation # ERP_PR_1301393620

Naval Medical Research Unit South is seeking research services to support its Virology Department’s febrile and respiratory surveillance study, specifically in support of a Zika virus study in Panama. The government has conducted market research and determined that only Fundacion Ciudad del Saber possesses the unique capability to fully meet the technical and operational requirements of the study, making the procurement eligible for a sole source award under FAR 13.106-1(b)(i). No competitive solicitation exists, and this notice serves solely as an opportunity for other potential vendors to demonstrate their capability to perform the work. Interested parties must submit a capability statement not exceeding five pages in 10-point font or larger, containing detailed management, technical, and cost information with convincing evidence of their ability to fulfill the requirement. Submissions must be sent via email as a Word or PDF attachment to genaro.m.vasquez.ln@health.mil with the subject line “ERP PR_1301393620” no later than 12:00 PM local time on August 11, 2026. Responses consisting only of questions or requests for clarification will not be accepted. The government retains full discretion to proceed with a sole source award or open a competitive process based on the submissions received. The contracting office is located in Washington, DC, and the primary point of contact is Genaro Vasquez.

Naval Medical Research Unit South

POSTED

DEADLINE

Recombinant Antibody Discovery & Engineering ServicesThe contract involves the discovery, humanization, and engineering of single domain antibodies designed to penetrate the blood-brain barrier using phage and yeast display platforms. This effort includes advanced antibody optimization through affinity maturation to enhance binding strength and specificity, as well as comprehensive stability testing to ensure functional integrity under physiological conditions. The work is scientifically focused on developing recombinant antibody formats capable of crossing the blood-brain barrier, a critical step for therapeutic applications targeting neurological diseases. This subcontract, issued by the National Institutes of Health under the Department of Health and Human Services, is classified under NAICS code 541714 for research and development in the physical, engineering, and life sciences. The opportunity was posted on July 24, 2026, with a response deadline of August 3, 2026. Performance is expected to take place in Bethesda, Maryland, 20892. The project does not specify a set-aside type or point of contact details, and the full solicitation can be accessed via the provided SAM.gov link for additional procedural or submission guidelines.

National Institutes Of Health Olao

POSTED

DEADLINE

Bioinformatics and Data Analysis for Biomarker ResearchThe contract titled Bioinformatics and Data Analysis for Biomarker Research seeks to deliver computational analysis of high-throughput sequencing data with the goal of identifying and validating biomarker signatures, accompanied by the generation of detailed research reports. This effort is classified as a subcontract under NAICS code 541714 and is managed by the Department of Veterans Affairs through its 245-NETWORK Contract Office 5. The work is to be performed at a location in Washington, D.C., with a zip code of 20422. The opportunity was posted on July 24, 2026, and responses are due by August 7, 2026, at 5:00 PM EST. Although no specific set-aside designation is indicated, the contract is structured to support advanced bioinformatics capabilities essential for translational research in biomarker discovery.

245-NETWORK Contract Office 5 (36C245)

POSTED

DEADLINE

Humanized single domain antibodies for therapeutic brain delivery

Solicitation # 75N98026Q00867

The National Institutes of Health Office of Extramural Research, under the Department of Health and Human Services, has issued a presolicitation for the development of humanized single domain antibodies designed for therapeutic delivery across the blood-brain barrier. The project, identified by solicitation number 75N98026Q00867, aims to advance novel antibody technologies capable of targeting brain-specific pathologies with enhanced precision and efficacy. All responses are due by August 3, 2026, and no set-aside provisions are applicable, meaning the opportunity is open to all eligible entities. The performance location is designated as Bethesda, Maryland, with the contract administration handled by the agency’s office at 20892. Primary point of contact for inquiries is Towanda Daniels, reachable via email at danielt@mail.nih.gov. The solicitation was posted on July 24, 2026, and all potential offerors are directed to the designated SAM.gov workspace for additional details and documentation. No NAICS code has been assigned at this stage, and the initiative reflects a strategic effort to enable breakthrough treatments for neurological disorders through innovative biotherapeutic platforms. Applicants must ensure full compliance with the requirements outlined in the attached Notice of Intent.

National Institutes Of Health Olao

POSTED

DEADLINE

Illumina Reagent Kits

Solicitation # 1301397256

The United States Department of the Naval Medical Research Command intends to award a sole source contract to Illumina, Inc. of San Diego, California, for the purchase of Illumina Reagent Kits. This procurement is not a competitive solicitation, but responses received will be considered if submitted. The action is classified under NAICS code 541714 and will be conducted under FAR Part 12 guidelines for commercial items. All vendors must be registered in the Systems for Award Management (SAM) and possess a Unique Entity Identification Number (UEI) to be eligible for award, with SAM registration available free of charge through sam.gov or by calling (866) 606-8220. The contract is identified by solicitation number 1301397256, posted on July 23, 2026, with a response deadline of August 7, 2026. The contracting office is located in Silver Spring, Maryland, with performance expected in Frederick, Maryland. Primary point of contact is Shamai Carter, reachable at shamai.m.carter.civ@health.mil, with Nataki Johnson as the secondary contact.

Naval Medical Research Center

POSTED

DEADLINE

AI-Driven Predictive Maintenance for Oilfield EquipmentThe contract titled AI-Driven Predictive Maintenance for Oilfield Equipment seeks to develop advanced AI and machine learning models designed to forecast failures in critical oilfield equipment including pumps, compressors, and valves. The primary objective is to reduce unplanned downtime by 20 percent through proactive maintenance scheduling enabled by predictive analytics. This subcontract is posted under the NAICS code 541714, which pertains to research and development in the physical, engineering, and life sciences, indicating a focus on technical innovation in industrial applications. The contract is managed by the National Energy Technology Laboratory under the Department of Energy, with a response deadline of September 22, 2026, and a posting date of July 23, 2026. While specific performance locations and points of contact are not detailed, the scope implies deployment across oilfield operations requiring real-time equipment monitoring and data-driven decision-making. Success will be measured by achieving the targeted reduction in downtime, demonstrating the model’s reliability and operational impact in high-stakes industrial environments.

National Energy Technology Laboratory

POSTED

DEADLINE

Limited Competition: Clinical and Translational Science Awards (CTSA) Program: Collaborative and Innovative Acceleration AwardThe Congressionally mandated Clinical and Translational Science Awards (CTSA) Program aims to accelerate the translation of scientific discoveries into practical treatments, diagnostics, and health interventions that enhance patient and public health by funding a national network of academic medical centers. This network provides essential infrastructure, expertise, training, and collaborative platforms needed to move research from the laboratory into clinical practice and community health settings. The current opportunity is a forecast for a limited competition soliciting applications for the Collaborative and Innovative Acceleration Award, designed to support the development and implementation of novel approaches, technologies, or models that amplify the impact of translational research and expedite the delivery of effective therapies to all populations. Funding is authorized under Sections 301 and 405 of the Public Health Service Act, and governed by Federal Regulations 42 CFR Part 52 and 2 CFR Part 200. Eligible organizations may apply under this limited competition, and proposals will undergo standard National Institutes of Health peer review, with funding awarded only to meritorious applications. The announcement is issued by the National Institutes of Health, under the Department of Health and Human Services, with specific inquiries directed to the Division of Clinical Innovation at NCATS. The forecast was posted on July 20, 2026, and further details can be accessed through the official grants.gov listing, though no set-aside type, NAICS code, or specific place of performance is indicated.

National Institutes Of Health

POSTED

13 days ago

DEADLINE

N/A

General Info

Agency

Agency For International Development → Usaid Bureau For Global HealthView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

DC, USA

Set-Aside

NONE

Documents

(2)

GlobalHealthBAA-Microbicides-2021+Amendment+01.docx

DOCX

BAA+Addendum+Microbicides+R+and+D.pdf

PDF

AI Contract Breakdown

Uniform Contract Format

What is UCF?

Uniform Contract Format (UCF) uses AI to break down any contract into standardized sections—scope, pricing, deliverables, and evaluation criteria.

Timeline

1 update

PhaseClosed

PostedJan 25

Solicitation

Amendment 1Feb 8

Contract was updated

Response DeadlineMar 11

Deadline has passed

Submission Closed

03/11/2021, 04:59:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyAgency For International Development → Usaid Bureau For Global Health

Contacts1 person available

OfficeWASHINGTON, DC, 20523, USA

Organization / Agency

Agency For International Development → Usaid Bureau For Global Health

View Agency Profile

Office AddressWASHINGTON, DC, 20523, USA

Contacts

Adrienne Shade

contact@example.gov

Full Description

The USAID Global Health Broad Agency Announcement for Research and Development (BAA) seeks opportunities to co-create, co-design, co-invest, and collaborate in the research, development, piloting, testing, and scaling of innovative, practical, and cost-effective interventions to address the most pressing problems in global health. The United States Agency for International Development (USAID) invites organizations and companies to participate with USAID to harness the power of science, technology, and innovation to generate and implement novel tools and approaches that accelerate and sustain improved health outcomes in developing countries. The Objective of this Addendum is to bring together a collaboration of partners with diverse, complementary, and relevant capabilities that, when combined, will accelerate the research and development (R&D) of new HIV prevention products that women can choose to protect themselves, and address the continuing and disproportionately high rates of HIV incidence in women, especially adolescent girls and young women in sub-Saharan Africa.